|
|
Volumn 323, Issue 21, 2020, Pages 2135-2136
|
|
Preserving Clinical Trial Integrity during the Coronavirus Pandemic
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ARTICLE;
BEHAVIOR THERAPY;
CHRONIC DISEASE;
CLINICAL OUTCOME;
CLINICAL PROTOCOL;
CLINICAL TRIAL (TOPIC);
CORONAVIRUS INFECTION;
DISEASE SEVERITY;
HEALTH CARE DELIVERY;
HIGH RISK POPULATION;
HUMAN;
INFECTION PREVENTION;
INFECTION SENSITIVITY;
MEDICAL CARE;
PANDEMIC;
PATIENT SAFETY;
PRIORITY JOURNAL;
PUBLIC HEALTH PROBLEM;
PUBLIC HEALTH SERVICE;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
RESEARCH SUBJECT;
RISK BENEFIT ANALYSIS;
SOCIAL ISOLATION;
TELECOMMUNICATION;
BETACORONAVIRUS;
E-MAIL;
HOSPITAL MANAGEMENT;
INTENTION TO TREAT ANALYSIS;
MEDICAL STAFF;
MOBILE PHONE;
PATIENT TRANSPORT;
PRACTICE GUIDELINE;
PROCEDURES;
QUALITY CONTROL;
QUESTIONNAIRE;
RISK ASSESSMENT;
TREATMENT OUTCOME;
VIRUS PNEUMONIA;
APPOINTMENTS AND SCHEDULES;
BETACORONAVIRUS;
CELL PHONE;
CORONAVIRUS INFECTIONS;
ELECTRONIC MAIL;
GUIDELINES AS TOPIC;
HUMANS;
INTENTION TO TREAT ANALYSIS;
MEDICAL STAFF;
PANDEMICS;
PATIENT SAFETY;
PNEUMONIA, VIRAL;
QUALITY CONTROL;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
RISK ASSESSMENT;
SURVEYS AND QUESTIONNAIRES;
TRANSPORTATION OF PATIENTS;
TREATMENT OUTCOME;
|
|
EID: 85082528685
PISSN: 00987484
EISSN: 15383598
Source Type: Journal
DOI: 10.1001/jama.2020.4689 Document Type: Article |
|
Times cited : (165)
|
|
References (3)
|
